Personalized mRNA Vaccine for Pancreatic Cancer after Surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a personalized mRNA vaccine made from your tumor’s unique genetic features. It is given after surgery to prevent the pancreatic cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had surgery to remove pancreatic cancer (a radical resection) and recovered well.
- You must have no signs of cancer spread to other organs after surgery.
- You must have good organ function (heart, liver, kidneys) as shown by recent lab tests.
- You cannot have an active, serious infection or a history of certain transplants or immune conditions.
- You must agree to use effective birth control during and for 6 months after the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine combined with an immunotherapy drug (PD-1 inhibitor) to prevent pancreatic cancer from returning after surgery. It is for patients whose tumors have specific genetic features and who cannot have standard chemotherapy.
This trial tests a personalized mRNA vaccine made from your own tumor's unique markers (neoantigens). It is for people with advanced pancreatic cancer that has spread or come back, and who have had limited or no prior chemotherapy. The goal is to see if this vaccine can help the immune system fight the cancer.
This trial tests a personalized mRNA vaccine (made from your tumor's unique markers) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to see if the vaccine can help prevent the cancer from coming back.
This trial tests a personalized mRNA vaccine designed to train your immune system to fight your specific cancer. It's for people who have just had surgery to remove a digestive system cancer (like pancreatic or colorectal) and will also receive standard chemotherapy after surgery.
This trial tests a personalized vaccine plus a drug that helps your immune system attack cancer cells (a PD-L1 blocker) in people who have just had surgery for pancreatic cancer. The goal is to see if the combination can prevent the cancer from coming back.
This trial tests a new mRNA vaccine (AK154) alone or with other immunotherapy drugs after successful pancreatic cancer surgery. It also looks at adding chemotherapy later. The goal is to see if this treatment can help prevent the cancer from coming back.
Hear when a new Pancreatic Cancer Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.